BRPI1013893A2 - uso de tetraidrobiopterina como um marcador e um agente terapêutico para a doença de fabry. - Google Patents

uso de tetraidrobiopterina como um marcador e um agente terapêutico para a doença de fabry.

Info

Publication number: BRPI1013893A2
Authority: BR; Brazil
Prior art keywords: tetrahydrobiopterin; marker; therapeutic agent; fabry disease; fabry
Prior art date: 2009-04-09

Application number

BRPI1013893A

Other languages

English (en)

Inventor

David F Moore

Erland Arning

Raphael Schiffmann

Teodoro G Bottiglieri

Original Assignee

Baylor Res Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-09

Filing date

2010-04-09

Publication date

2016-04-05

2010-04-09 Application filed by Baylor Res Inst filed Critical Baylor Res Inst

2016-04-05 Publication of BRPI1013893A2 publication Critical patent/BRPI1013893A2/pt

Links

208000024720 Fabry Disease Diseases 0.000 title 1
239000003814 drug Substances 0.000 title 1
239000003550 marker Substances 0.000 title 1
FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 title 1
229960004617 sapropterin Drugs 0.000 title 1
229940124597 therapeutic agent Drugs 0.000 title 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Urology & Nephrology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Food Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Pathology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Cardiology (AREA)
Diabetes (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)

BRPI1013893A 2009-04-09 2010-04-09 uso de tetraidrobiopterina como um marcador e um agente terapêutico para a doença de fabry. BRPI1013893A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16815009P	2009-04-09	2009-04-09
US12/757,420 US8410101B2 (en)	2009-04-09	2010-04-09	Use of tetrahydrobiopterin as a marker and a therapeutic agent for fabry disease
PCT/US2010/030552 WO2010118330A2 (en)	2009-04-09	2010-04-09	Use of tetrahydrobiopterin as a marker and a therapeutic agent for fabry disease

Publications (1)

Publication Number	Publication Date
BRPI1013893A2 true BRPI1013893A2 (pt)	2016-04-05

Family

ID=42934560

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1013893A BRPI1013893A2 (pt)	2009-04-09	2010-04-09	uso de tetraidrobiopterina como um marcador e um agente terapêutico para a doença de fabry.

Country Status (10)

Country	Link
US (1)	US8410101B2 (pt)
EP (1)	EP2416776A4 (pt)
JP (1)	JP5463410B2 (pt)
KR (1)	KR20120022849A (pt)
CN (1)	CN102387803A (pt)
AU (1)	AU2010233147B2 (pt)
BR (1)	BRPI1013893A2 (pt)
CA (1)	CA2756272A1 (pt)
MX (1)	MX2011010565A (pt)
WO (1)	WO2010118330A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011109448A1 (en) *	2010-03-05	2011-09-09	Baylor Research Institute	Involvement of androgen/androgen receptor pathway in fabry disease
WO2013055954A1 (en)	2011-10-11	2013-04-18	The Regents Of The University Of California	Biomarker for abdominal aortic aneurysm
KR101913199B1 (ko) *	2016-03-18	2018-10-31	울산대학교 산학협력단	파브리병 진단용 바이오마커 및 이의 용도
US12020820B1 (en)	2017-03-03	2024-06-25	Cerner Innovation, Inc.	Predicting sphingolipidoses (fabry's disease) and decision support
US11335461B1 (en)	2017-03-06	2022-05-17	Cerner Innovation, Inc.	Predicting glycogen storage diseases (Pompe disease) and decision support
US11923048B1 (en)	2017-10-03	2024-03-05	Cerner Innovation, Inc.	Determining mucopolysaccharidoses and decision support tool
US12313635B2 (en)	2018-07-27	2025-05-27	The Regents Of The University Of California	Biomarker for thoracic aortic aneurysm
CN114814063A (zh) *	2022-04-08	2022-07-29	宁波熙宁检测技术有限公司	一种检测人体内四氢生物蝶呤的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5925323A (ja) *	1982-03-03	1984-02-09	鐘淵化学工業株式会社	プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US6544994B2 (en)	2000-06-07	2003-04-08	Eprov Ag	Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
JP4251485B2 (ja) *	2003-08-20	2009-04-08	生化学工業株式会社	糖脂質の測定法、疾病検出方法及びキット
WO2005048926A2 (en) *	2003-11-13	2005-06-02	The General Hospital Corporation	Methods for treating pain
US7297810B2 (en) *	2004-12-30	2007-11-20	3M Innovative Properties Company	High refractive index monomers for optical applications
KR100759716B1 (ko) *	2006-09-26	2007-10-04	고려대학교 산학협력단	복합기능 자성체 코어 - 반도체 쉘 나노 입자 및 그의제조방법
WO2008075957A1 (en) *	2006-12-21	2008-06-26	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Treatment of fabry disease
WO2008075959A1 (en) *	2006-12-21	2008-06-26	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Diagnostic marker for fabry disease

2010
- 2010-04-09 CA CA2756272A patent/CA2756272A1/en not_active Abandoned
- 2010-04-09 WO PCT/US2010/030552 patent/WO2010118330A2/en not_active Ceased
- 2010-04-09 US US12/757,420 patent/US8410101B2/en not_active Expired - Fee Related
- 2010-04-09 CN CN2010800160689A patent/CN102387803A/zh active Pending
- 2010-04-09 EP EP10762501A patent/EP2416776A4/en not_active Withdrawn
- 2010-04-09 KR KR1020117025920A patent/KR20120022849A/ko not_active Ceased
- 2010-04-09 BR BRPI1013893A patent/BRPI1013893A2/pt not_active Application Discontinuation
- 2010-04-09 AU AU2010233147A patent/AU2010233147B2/en not_active Expired - Fee Related
- 2010-04-09 JP JP2012504889A patent/JP5463410B2/ja not_active Expired - Fee Related
- 2010-04-09 MX MX2011010565A patent/MX2011010565A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2010118330A3 (en)	2011-03-31
AU2010233147A1 (en)	2011-10-13
EP2416776A2 (en)	2012-02-15
US8410101B2 (en)	2013-04-02
US20100260747A1 (en)	2010-10-14
JP5463410B2 (ja)	2014-04-09
CA2756272A1 (en)	2010-10-14
CN102387803A (zh)	2012-03-21
EP2416776A4 (en)	2012-09-26
MX2011010565A (es)	2011-10-19
WO2010118330A2 (en)	2010-10-14
KR20120022849A (ko)	2012-03-12
JP2012523570A (ja)	2012-10-04
AU2010233147B2 (en)	2012-10-25

Similar Documents

Publication	Publication Date	Title
PT2504005E (pt)	2014-01-10	Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas
BRPI0908428A2 (pt)	2015-12-08	uso de ranozalina para tratar a dor.
BRPI1013893A2 (pt)	2016-04-05	uso de tetraidrobiopterina como um marcador e um agente terapêutico para a doença de fabry.
BR112013016772A2 (pt)	2016-10-11	composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
BR112013013311A2 (pt)	2017-09-19	agente terapêutico de indução de citotoxicidade
BRPI1012116A2 (pt)	2016-03-15	composição farmacêutica para o tratamento de doenças cardíacas
CL2014003232A1 (es)	2015-03-13	Formulaciones y métodos para la administración vaginal de antiprogestinas.
BRPI0907036A2 (pt)	2015-07-07	Conjunto de máscara para fornecer gás para um paciente, e, kit de conjunto de máscara para fornecer um gás para um paciente.
BR112013014934A2 (pt)	2016-09-13	um leito de via férrea de poliuretano, um método de preparação e o uso do mesmo
ZA201209145B (en)	2014-02-26	Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
BRPI0819630A2 (pt)	2015-05-05	Montagem de interface de paciente para terapia respiratória
BRPI1008498A2 (pt)	2015-08-25	Composto, prodroga do composto, medicamento, e, uso de um composto.
GT201200313A (es)	2014-01-31	5-fluoro-1h-pirazolopiridinas sustituidas y su uso
IL216876A (en)	2016-04-21	Cationic lipid, lipid formulations comprising same and use thereof in the preparation of therapeutic agents for delivering to cells
BR112012016398A2 (pt)	2018-08-21	Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
BRPI0921802A8 (pt)	2018-03-13	uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo.
BRPI0817198A2 (pt)	2015-03-17	(ciclopropilfenil)feniloxalamidas, método para a produção das mesmas, e uso das mesmas como um medicamento
BRPI1013698A2 (pt)	2016-04-26	métodos para tratamento com o uso de terapia de combinação
BRPI0719523A2 (pt)	2015-06-16	Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes
BRPI1009372A2 (pt)	2016-05-31	compostos, composição farmacêutica e respectivos usos
BRPI0821248A2 (pt)	2015-06-16	Inibidores de cinesina como fármacos terapêuticos para câncer
BRPI0917026A2 (pt)	2016-02-16	uso de sucralose como agente granulador
BRPI1011412A2 (pt)	2016-03-15	composição para liberação sustentada de droga compreendendo alutinante geopolimérico
BR112015012443A2 (pt)	2017-07-11	composição de limpeza, método de limpeza do corpo humano, uso da composição e método para prover limpeza
PT2525796T (pt)	2016-07-11	Solução aquosa incluindo 3-quinuclidinonas para o tratamento de doenças hiperproliferativas, auto-imunes e cardíacas

Legal Events

Date	Code	Title	Description
2016-05-31	B11A	Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
2016-08-16	B11Y	Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]